A Phase 1 Study of the Safety, Tolerability, and Pharmacokinetics of INCMGA00012 in Patients With Advanced Solid Tumors
Phase of Trial: Phase I
Latest Information Update: 18 Apr 2018
At a glance
- Drugs MGA 012 (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Incyte Corporation; MacroGenics
- 11 Apr 2018 Planned End Date changed from 1 Dec 2018 to 1 Jul 2021.
- 11 Apr 2018 Planned primary completion date changed from 1 Dec 2018 to 1 Jul 2021.
- 27 Feb 2018 According to a MacroGenics media release, patients are being enrolled across multiple dose expansion cohorts.